PLoS By Category | Recent PLoS Articles

Infectious Diseases - Pediatrics and Child Health - Public Health and Epidemiology

Retrospective Study of the Incidence of HFMD and Seroepidemiology of Antibodies against EV71 and CoxA16 in Prenatal Women and Their Infants
Published: Friday, May 25, 2012
Author: Feng-Cai Zhu et al.

by Feng-Cai Zhu, Zheng-Lun Liang, Fan-Yue Meng, Ying Zeng, Qun-Ying Mao, Kai Chu, Xue-Fang Song, Xin Yao, Jing-Xin Li, Hong Ji, Yi-Ju Zhang, Liang Li, Hong-Xing Pan, Ke Xu, Wei-Ming Dai, Wei-Wei Zhang, Fei Deng, Hua Wang, Jun-Zhi Wang


Hand, foot, and mouth disease (HFMD) has been emerging as an important public problem over the past few decades, especially in Asian and Pacific regions. A national program on EV71 vaccine development against HFMD was initiated in China, in 2008, which called for a need for seroepidemiological study for the target population.

Methodology/Principal Findings

This was a retrospective study conducted in Jiangsu Province, in October, 2010. We measured the neutralizing antibodies against EV71 and CoxA16 in a cohort of infants aged of 2, 7, 12, and 27–38 months and their mothers just before delivery. Series sera samples from 975 infants and 555 mothers were collected and analyzed. Questionnaires on the history of HFMD were completed in the survey. A total of 143 HFMD cases were collected, but only 11.2% were reported to the National Infectious Disease Information Management System. The level of maternal antibody titers decreased dramatically during the first 7 month and remained at a relatively low level thereafter. But it increased significantly from month 12 to months 27–38. The accumulate incidence density of HFMD demonstrated a significant increase after 14 months of age, resulting in a accumulate incidence density of 50.8/1000 person-years in survey period. Seropositivity of EV71 antibody in infants at the age of 2 months seems to demonstrate a protective effect against HFMD.

Conclusions and Significance

High seropositive rate of EV71 and CoxA16 antibody was found in prenatal women in mainland China, and there is a need to enhance the HFMD case management and the current surveillance system. We suggest that infants aged between 6 to 14 months should have the first priority to receive EV71 vaccine.